The problem of decompensated heart failure: Nomenclature, classification, and risk stratification

American Heart Journal

Volumn 145, Issue 2 SUPPL., 2003, Pages

  Felker, G Michael ^a   Adams Jr , Kirkwood F ^b   Konstam, Marvin A ^c   O'Connor, Christopher M ^a   Gheorghiade, Mihai ^d  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; HUMAN; LUNG EDEMA; MORBIDITY; MORTALITY; NOMENCLATURE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 0037323582     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.150     Document Type: Conference Paper

References (54)

1. Bonneux L, Barendregt JJ, Meeter K, et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Pub Health 1994;84:20-8.
2. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73.
3. American Heart Association. 2002 Heart and stroke statistical update. American Heart Association: Dallas; 2002.
4. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99-104.
5. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
6. McAlister FA, Lawson FM, Teo KK, et al. A systemic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-84.
7. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous Milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-8.
8. O'Connell JB. The economic burden of heart failure. Clin Cardiol 2000;23(3 Suppl):III-6-10.
9. Ramirez A, Abelmann WH. Cardiac decompensation. N Engl J Med 1974;290:499-501.
10. Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998;135(Suppl):S204-15.
11. McCarthy RE III, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000;342:690-5.
12. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140:840-7.
13. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-74.
14. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function: clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996;156:146-57.
15. Carson P, Johnson G, Fletcher R, et al. Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 1996;27:642-9.
16. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
17. McDermott MM, Feinglass J, Lee PI, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997;134:728-36.
18. Bart BA, Shaw LK, McCants CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997;30:1002-8.
19. Felker GM, Thompson RE, Hare JM, et al. Underlying cause and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
20. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-8.
21. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
22. Unverferth DV, Magorien RD, Lewis RP, et al. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983;105:176-9.
23. Pasternac A, Noble J, Streulens Y, et al. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982;65:778-89.
24. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J 1998;135(Suppl):S293-309.
25. Shah MS, Hasselblad V, Stinnett SS, et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Failure 2001;7:105-13.
26. Shah MR, O'Connor CM, Sopko G, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J 2001;141:528-35.
27. Schocken D, Arrieta M, Leaverton P, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-6.
28. Adams KF, Sueta CA, Gheorghiade M, et al. Gender differences in survival in advanced heart failure: insights from the FIRST Study. Circulation 1999;99:1816-21.
29. Petrie MC, Dawson NF, Murdoch DR, et al. Failure of women's hearts. Circulation 1999;99:2334-41.
30. Ho KL, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
31. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16.
32. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
33. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail 1999;5:178-87.
34. The Beta-Blocker Evaluation of Survival Trial (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced heart failure. N Engl J Med 2001;344:1659-67.
35. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.
36. Michalsen A, Konig GTW. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998;80:437-41.
37. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure: Traits among urban blacks. Arch Intern Med 1988;148:2013-6.
38. Opasich C, Febo O, Riccardi PG, et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol 1996;78:354-7.
39. Kimmelstiel CD, Levine D, Perry K, et al. Randomized controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF Trial [abstract]. J Am Coll Cardiol 2001;37(2A Suppl):219.
40. Stewart S, Vandenbroek AJ, Pearson S, et al. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999;159:257-61.
41. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
42. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
43. Brophy JM, Deslouriers G, Rouleau JL. Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1994;10:543-7.
44. Brophy JM, Deslauriers G, Boucher B, et al. The hospital course and short-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1993;9:219-24.
45. Harajai KJ, Thompson HW, Turget T, et al. Simple clinical variables are markers of the propensity for readmission in patients hospitalized with heart failure. Am J Cardiol 2001;87:234-7.
46. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000;101:2557-67.
47. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
48. Cohen M, Stinnett SS, Weatherley BD, et al. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J 2000;139:962-70.
49. Brener SJ, Ellis SG, Sapp SK, et al. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. Am Heart J 2000;139:476-81.
50. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
51. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996-3007.
52. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine in associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 2000;138:78-86.
53. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
54. Del Carlo C, Barretto AC, O'Connor CM, et al. Cardiac troponin T for risk stratification in decompensated heart failure [abstract]. J Am Coll Cardiol 2001;37(2 Suppl):189A.